Sotac Pharmaceuticals is a contract manufacturer that turns other companies’ drug formulas into finished pills, capsules, syrups and creams - it does not sell to patients. Founded as a partnership in 2015 and listed on the NSE Emerge platform in April 2023, the company has grown by adding specialised factories under separate subsidiaries, each focused on a distinct production technology or product type. The recurring approach is to build WHO-GMP accredited capacity in the Sanand pharmaceutical hub of Gujarat, lock in large Indian and global pharma marketers as clients, and then replicate the model in adjacent categories - antibiotics, nutraceuticals, and eventually its own research - so that each new unit rides on the same contract-manufacturing relationships and quality reputation.
Business segments
A single contract-manufacturing engine expressed through four production verticals - general medicines, antibiotics, nutraceuticals and R&D - each housed in a separate subsidiary and all serving the same roster of pharma marketers.
1. Non-beta-lactam formulations: the core factory that built the client list
This unit makes the everyday tablets, capsules and liquids that account for nearly all of the company’s output, serving more than 160 pharma marketers on a contract or loan-licence basis.
- Scale that wins orders - the plant can produce 360 crore tablets and 32.4 crore capsules a year, plus 2,160 kilolitres of syrups and 324 tonnes of ointments and creams, giving it the capacity to handle large, recurring orders from national and multinational clients.
- A licence library that opens doors - it holds manufacturing permission for 329 products under one FDA licence and 45 under another, and is permitted to sell 34 of those products under its own name in export markets, so it can offer a ready-made catalogue rather than starting from scratch for each client.
- Tablets are the backbone - in FY25, tablets represented roughly 92% of this unit’s sales, with capsules, ointments and liquids making up the rest, which means the factory is optimised around high-volume solid-dosage production.
- Clients include the names a pharmacist would recognise - past and present customers include Cadila, J.B. Chemicals, Lincoln Pharma, Intas, Viatris (Mylan), Ipca, Eris Lifesciences and others, giving the company a credential that helps win new business.
- Location as a production advantage - the plant sits in the Sanand GIDC II estate on the outskirts of Ahmedabad, a recognised hub for pharma contract manufacturing with good road and port connectivity for both domestic distribution and exports to over 20 countries.
2. Beta-lactam formulations: the antibiotics unit kept separate for safety
Housed in a 71%-owned subsidiary, this facility makes penicillin-group antibiotics in an isolated plant designed to prevent cross-contamination - same contract-manufacturing model, different regulatory logic.
- Built for containment - the plant is laid out to keep beta-lactam production physically separated from other manufacturing, with dedicated processes and sections that meet the highest safety and environmental standards required for antibiotic handling.
- A second licence bank - the subsidiary holds manufacturing permission for around 335 products under a single FDA licence and can sell three products under its own name in export markets, mirroring the parent unit’s strategy of offering pre-approved formulations.
- Capacity sized for the antibiotic opportunity - the Beta-Lactam facility under SOTAC Healthcare Private Limited can produce 32.4 crore tablets, 21.6 crore capsules and 2.16 crore dry syrup bottles annually, adding a parallel production line that serves the same 162-plus corporate clients without competing with the main factory.
3. Nutraceutical and food products: the new factory with a ten-year anchor client
Operated through a majority-held subsidiary, this vertical has two units - one already making tablet-coating materials exclusively for Kerry Group of Ireland under a decade-long contract, the other built for complex generic and nutraceutical formulations.
- An anchor tenant from day one - Unit I runs under a 10-year loan-licence agreement signed in July 2024 with Kerry Ingredients India, a subsidiary of the Ireland-based taste and nutrition giant, producing ready-mix coating materials at a dedicated Sanand facility with a contract value of roughly Rs. 106 crore over the term.
- Built for complexity - Unit II is equipped for modified-release tablets, suspensions and immediate-release dosage forms across allopathic, healthcare, nutraceutical and ayurvedic products, with modern equipment that targets harder-to-make formulations where contract-manufacturing competition is thinner.
4. Molecule research and development: the in-house lab that feeds the factories
A wholly owned subsidiary runs a formulations lab with over 10 scientists - it does not sell R&D services to outsiders but develops new products that the manufacturing units can then offer to their contract clients.
- A catalogue-expansion engine - the R&D centre develops oral solids and oral liquid, creating new formulations that the parent and subsidiary factories can add to their licence libraries and pitch to existing clients.
- Access to high-end instruments without owning them all - through collaborations, the lab can use advanced analytical equipment including a Differential Scanning Calorimeter, Zeta Sizer, XRD, Atomic Force Microscope and LC/MS/MS, giving it the analytical firepower of a larger organisation while keeping capital costs down.
Group structure and partners
Three operating subsidiaries sit under a listed parent, each with a distinct manufacturing or R&D role, all controlled by a promoter group with six decades of combined pharma experience.
- Sotac Healthcare Private Limited - the 71%-owned subsidiary that runs the beta-lactam antibiotics plant, keeping penicillin production legally and physically ring-fenced from the main factory.
- Sotac Research Private Limited - the wholly owned R&D subsidiary that develops new formulations exclusively for the group’s own manufacturing use.
- Sotac Lifesciences Private Limited - the majority-held subsidiary (stake increased to 51.26% during FY24) that operates both the Kerry Ingredients coating-materials unit and the larger nutraceutical and complex-generics facility.
- Promoter leadership - Chairman and Managing Director Sharadkumar Patel (MBA in Operations Management, Bachelor of Pharmacy, over 18 years of industry experience) leads a four-person executive director team, with common directorships across the subsidiaries ensuring unified control.
- Arm’s-length dealings - the parent and subsidiaries buy and sell raw materials, packing material and finished goods among themselves, all conducted in the ordinary course of business and priced at arm’s length.